This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by an unrestricted research grant from Nordic Pharma.
Reference
van Oijen M, et al. S-1 is a cost-effective alternative to capecitabine in metastatic colorectal cancer. 22nd World Congress on Gastrointestinal Cancer : abstr. SO-19, 1 Jul 2020. Available from: URL: https://www.sciencedirect.com/science/article/pii/S0923753420393339
Rights and permissions
About this article
Cite this article
S-1 + capecitabine cost-effective option in metastatic colorectal cancer. PharmacoEcon Outcomes News 859, 27 (2020). https://doi.org/10.1007/s40274-020-7036-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7036-6